Regeneron Reports the US FDA Accelerated Approval of Otarmeni (Lunsotogene Parvec-Cwha) in Genetic Hearing Loss

Why It Matters

The approval introduces the first gene‑therapy option for OTOF‑related hearing loss, addressing a sizable unmet need and setting a regulatory precedent for rare‑disease treatments.

Key Takeaways

• Otarmeni received FDA accelerated approval for OTOF‑related hearing loss
• Trial enrolled 20 patients; 80% achieved ≤70 dB HL at 24 weeks
• Half the cohort received unilateral treatment, half bilateral, expanding safety data
• 42% of responders reached normal hearing thresholds (≤25 dB HL)
• Regeneron will provide Otarmeni free of charge in the United States

Pulse Analysis

The U.S. Food and Drug Administration granted Regeneron’s Otarmeni (lunsotogene parvec‑cwha) accelerated approval, marking the first gene‑therapy authorization for hereditary sensorineural hearing loss caused by biallelic OTOF variants. The decision leverages the agency’s CNPV (Conditional New Product Validation) pathway, which allows earlier market entry when a therapy addresses an unmet medical need and demonstrates a reasonable benefit‑risk profile. By targeting the OTOF gene, Otarmeni restores the function of inner‑hair‑cell synapses, a mechanism not addressed by conventional hearing aids or cochlear implants.

Clinical evidence comes from the Phase I/II CHORD trial, which enrolled 20 participants aged 10 months to 16 years. Ten patients received a single‑ear injection while the remaining ten were treated bilaterally, providing early safety signals for both dosing strategies. At 24 weeks, 80 % of subjects achieved a pure‑tone average of 70 dB HL or better, and 70 % reached auditory brainstem response thresholds of 90 dB or lower. Notably, five patients (42 %) attained normal hearing levels (≤25 dB HL), and benefits persisted through week 48.

Regeneron’s decision to supply Otarmeni at no cost in the United States underscores a strategic push to accelerate adoption and generate real‑world data across a global enrollment effort that now includes the UK, Spain, Germany and Japan. The therapy’s approval could reshape the market for pediatric hearing loss, prompting insurers and providers to reconsider coverage models for gene‑based interventions. Moreover, Otarmeni sets a precedent that may encourage other biotech firms to pursue accelerated pathways for rare‑disease gene therapies.